TT 12

Drug Profile

TT 12

Alternative Names: HP-VST - Tessa Therapeutics; Human papillomavirus specific T cells - Tessa Therapeutics; TT12; TT12-HP VST

Latest Information Update: 11 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Tessa Therapeutics
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical cancer; Oropharyngeal cancer

Most Recent Events

  • 30 Sep 2015 Phase-I clinical trials in Cervical cancer in USA (IV)
  • 30 Sep 2015 Phase-I clinical trials in Oropharyngeal cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top